INTRODUCTION
Abacavir (ABC) is a nucleoside analogue reverse transcriptase inhibitor (NRTI) with activity against human immunodeficiency virus (HIV) (1) . It is administered as a second-line drug in combination with other antiretroviral agents according to the World Health Organization guidelines (2) . The most important adverse effect of ABC that limits its usage is an immunologically mediated hypersensitivity reaction that occurs in 5% -8% of Caucasian patients receiving highly active antiretroviral therapy (HAART) (1, 3) . ABC HSR is a life threatening clinical syndrome that affects multiple organ systems; it is characterized by constitutional symptoms (malaise,
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Tanaffos 2016; 15 (1) : [48] [49] [50] [51] [52] headache, and dizziness), fever, rash, gastrointestinal symptoms (nausea, vomiting, and diarrhea), and respiratory symptoms (dyspnea, and cough). The nonspecific symptoms of HSR may lead to clinical overdiagnosis, which may prevent patients from receiving ABC containing regimen (4) .
The relationship between HLA class I allele, HLA-B*5701, and ABC HSR was first reported by Mallal et al. (5) in Australian patients. Subsequent studies showed that genetic susceptibility to ABC HSR is strongly associated with the presence of HLA-B*5701 in different populations (4) . While the frequency of HLA-B*5701 has been reported in different ethnic groups (6.5% in Caucasians, 1% in subSaharan African, 5% to 20% in India, 4% to 10% in Thailand, 1% to 2% in the Mediterranean and ~0% in Korea), there are few reports from the Middle Eastern countries that estimate the prevalence of this allele in healthy patients (2.7% in Morocco, and 1% in Jordan) (6) (7) (8) (9) (10) (11) . It has been shown that screening for HLA-B*5701 could significantly reduce the incidence of ABC HSR (6).
To our knowledge, there are no data on the prevalence of HLA-B*5701 allele in Iranian HIV positive patients. Therefore, our goal was to assess the prevalence of HLA-B*5701 in our patients and evaluate its relationship with ABC HSR. 
MATERIALS AND METHODS
Study design
Sample size calculation
Caucasians have the closest ethnicity to Iranians (13) and our sample size was calculated using the prevalence of HLA-B*5701 allele in Caucasian patients of European heritage (14) . The minimum number of subjects required to estimate the frequency of the allele was calculated to be 176 patients.
DNA extraction and HLA typing
DNA from blood samples was prepared according to the methods described in the High Pure Viral Nucleic Acid Kit (Roche, Germany). The quality of the extracted genome in the specimen for PCR assay was evaluated by the detection of the beta-globin housekeeping gene using the GH20/PC04 primer set (15) .
HLA typing was carried out according to previously described methods (16) . The primers used in the study Of the four patients with suspected ABC HSR, two were excluded because their reactions were thought to be caused by concurrent medication administration according to Naranjo ADR Probability Scale (17) . The third patient, who had an incomplete drug history, was also excluded. Only one patient that experienced HSR based on Naranjo ADR Probability Scale was HLA-B*5701 carrier. There was no relationship between the history of allergy and ABC HSR.
Fisher's exact test showed a relationship between HSR and HLA-B*5701 (P=0.036). (23), Spain (24), France (25) , and the USA (26).
However, the structure of health care system in a country is a determining factor for health economic evaluation. Our results could be used to design a cost-effectiveness study for HLA-B*5701 screening in our country.
CONCLUSION
The prevalence of HLA-B*5701 in our HIV positive patients is lower than that in Caucasians but comparable with that in other Middle Eastern populations.
Pretreatment screening may reduce the incidence of ABC HSR, as well as its clinical over-diagnosis. However, economic issues should be considered. We suggest future economic feasibility studies to determine the necessity of this test in Iranian patients.
